Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome
Top Cited Papers
Open Access
- 3 February 2026
- journal article
- research article
- Published by Springer Nature in Nature Aging
- Vol. 6 (2) , 368-392
Abstract
Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) treatments, yet clinical outcomes remain poor. Cellular senescence and its associated secretory phenotype (SASP) can have multiple tumor-promoting activities, but both are largely unexplored in these cancers. In this study, using xenograft, orthotopic and Kras G12V -driven murine NSCLC models, we demonstrate that cisplatin-induced senescence strongly promotes malignant phenotypes and tumor progression, which is stimulated by aging. Mechanistically, we found that a transforming growth factor-beta (TGFβ)-enriched SASP drives pro-proliferative effects through TGFBR1 and AKT/mTOR. TGFBR1 inhibition with galunisertib or senolytic treatment reduces tumor progression driven by cisplatin-induced senescence, and concomitant use of TGFBR1 inhibitors with platinum-based chemotherapy reduces tumor burden and improves survival. Finally, we validate the translational relevance of tumor-promoting TGFβ-enriched SASP using clinical NSCLC and HGSOC samples from patients who received neoadjuvant platinum-based chemotherapy. Together, our findings identify a potential cancer therapy resistance mechanism and provide preclinical proof of concept for future trials.Keywords
This publication has 73 references indexed in Scilit:
- Clinical development of therapies targeting TGFβ: current knowledge and future perspectivesAnnals of Oncology, 2020
- Cellular senescence in cancer: from mechanisms to detectionMolecular Oncology, 2020
- Cellular Senescence: Defining a Path ForwardCell, 2019
- Notch Signaling Mediates Secondary SenescenceCell Reports, 2019
- c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK SignalingCancer Cell, 2018
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 2017
- Transforming Growth Factor-Beta Induces Senescence in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth†,‡Hepatology, 2010
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- TGFβ in CancerCell, 2008
- The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to PaclitaxelCancer Cell, 2007